ANI Pharma (ANIP) Tops Q4 EPS by 8c, Revenues Beat; Offers FY19 EPS/Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ANI Pharmaceuticals Reports Record Full Year and Fourth Quarter 2018 Results and Provides 2019 Guidance
February 27, 2019 8:30 AM ESTBAUDETTE, Minn., Feb. 27, 2019 /PRNewswire/ --
For the full year ended December 31, 2018:
Record net revenues of $201.6 million, an increase of 14% versus 2017 GAAP net income of $15.5 million and diluted GAAP earnings per share of $1.30 Adjusted non-GAAP EBITDA of $84.4 million Adjusted non-GAAP diluted earnings per share of $5.07For the fourth quarter 2018:
Record net revenues of $57.1 million, an increase of 21% versus 2017 GAAP net income of $5.4 million and diluted GAAP earnings per share of $0.46 Adjusted non-GAAP EBITDA of $22.2 million... More